ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1717

Identifying Patterns of Histopathologic Presentation in CNS Vasculitis

Chan Mi Lee1, Richard Prayson 2, Marcia Leon Rabanal 3, Leonard Calabrese 3 and Rula Hajj-ali 3, 1Cleveland Clinic Lerner College of Medicine of Case Western Reserve University/Cleveland Clinic, Cleveland, OH, 2Anatomic Pathology/Cleveland Clinic, Cleveland, OH, 3Rheumatologic and Immunologic Disease/Cleveland Clinic, Cleveland, OH

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: CNS Vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Primary central nervous system vasculitis (CNS-V) is vasculitis confined to the brain, spinal cord and meninges. It is a rare condition with unknown pathogenesis. Brain biopsy is the gold standard for the diagnosis of CNS-V, which histologically is marked by transmural inflammation of small and medium-sized leptomeningeal and parenchymal arterial vessels. This study aimed to analyze in depth other histopathologic features that may better distinguish CNS-V from other non-CNS-V conditions.

Methods: We identified patients who had brain biopsy and who were enrolled in the prospective CNS Vasculopathy Bioregistry at the Cleveland Clinic between 2012 and 2019. Registry participants are enrolled in both outpatient and inpatient settings based on differential diagnosis of CNS-V or a mimic of its symptoms. Out of 33 patients included, 19 were diagnosed with CNS-V according to (Calabrese and Mallek, 1988). Fourteen patients had uncertain diagnosis or diagnosis not consistent with CNS-V. Pathology reports were analyzed looking for documented  inflammatory cell types (T cells, B cells, macrophages, reactive astrocytes, plasma cells, and giant cells) and other histological features (granuloma/epithelioid histiocytes, necrotizing vasculitis, infection, neuronal loss, myelin loss, and amyloid deposits), each categorized by the presence (‘yes/no’) of cell type or histological feature, abundance (‘scant’ or ‘abundant’), confirmation by staining (‘yes/no’), and localization (‘transmural’ or ‘perivascular’).

Results: Our cohort consisted of mostly white (~90%), male (≥50%) and middle-aged (48.6±15.8 years; age at biopsy) individuals who had undergone 1.15±0.44 biopsies. Both CNS-V and non-CNS-V cases had the right side (53% and 64%) and frontal lobe (35% and 29%) as the most affected sites. Patients with diagnosis of CNS-V were more likely to have vascular wall infiltration by T cells (33% vs 10%), B cells (20% vs 10%), macrophages (18% vs 0%), and reactive astrocytes (22% vs 0%), and more prevalence of necrotizing vasculitis (11.8% vs 0%). Perivascular distribution was conversely lower in CNS-V than non-CNS-V, noted in 42% vs 70% for T cells, 40% vs 60% for B cells, and 18% vs 20% for macrophages.

Conclusion: In this retrospective study, we took a broad approach of comparing brain biopsies of patients with or without CNS-V to identify histopathological features that may be unique or more predictive of CNS-V. Intramural infiltration of inflammatory cells was more specific to the diagnosis of CNS-V than findings of perivascular inflammatory process. The presence of perivascular inflammation is nonspecific and is more common in non-CNS-V specimens.  

Reference: Calabrese, L.H. and Mallek, J.A. (1988) Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine (Baltimore) 67, 20–39


Disclosure: C. Lee, None; R. Prayson, None; M. Leon Rabanal, None; L. Calabrese, AbbVie, 8, Amgen, 5, Bristol-Myers Squibb, 8, Crescendo, 8, Genentech, 8, GlaxsoSmithKline, 5, Horizon, 5, Janssen, 5, 8, Pfizer, 5, Sanofi-Regeneron, 5, UCB, 5, 8; R. Hajj-ali, None.

To cite this abstract in AMA style:

Lee C, Prayson R, Leon Rabanal M, Calabrese L, Hajj-ali R. Identifying Patterns of Histopathologic Presentation in CNS Vasculitis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/identifying-patterns-of-histopathologic-presentation-in-cns-vasculitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identifying-patterns-of-histopathologic-presentation-in-cns-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology